Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.

Robert R HenryJulio RosenstockJohn F McCarthyGinger CarlsTom AlessiJohn YeeMichelle Baron

Published in: Diabetes, obesity & metabolism (2017)

ITCA 650 added to metformin for patients with T2D, and for those who switched to ITCA 650 from Ex-BID, meaningfully improved glucose control and significantly increased overall treatment satisfaction.

Keyphrases

physical activity
type diabetes
metabolic syndrome
adipose tissue
ultrasound guided
insulin resistance
replacement therapy